Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia

Pediatr Blood Cancer. 2009 Mar;52(3):426-8. doi: 10.1002/pbc.21795.

Abstract

A 15-year-old male with beta-thalassemia major developed dilated cardiomyopathy secondary to iron-overload (Z-scores of left ventricle (LV) dimensions >3, ejection fraction (EF) 33%). Treatment with deferoxamine was unsuccessful, presumably due to poor compliance. After 15 months of using deferasirox (DFX), LV end-diastolic dimension normalized (Z-scores <2), and EF improved to 58%. We conclude that treatment with DFX resulted in a reversal of iron-induced cardiomyopathy.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Benzoates / therapeutic use*
  • Cardiomyopathy, Dilated / blood*
  • Cardiomyopathy, Dilated / complications*
  • Deferasirox
  • Humans
  • Iron / blood*
  • Male
  • Triazoles / therapeutic use*
  • beta-Thalassemia / blood*
  • beta-Thalassemia / complications
  • beta-Thalassemia / drug therapy*

Substances

  • Benzoates
  • Triazoles
  • Iron
  • Deferasirox